Drug Use Investigation of Regorafenib/STIVARGA for Gastrointestinal Stromal Tumor Progressed After Cancer Chemotherapy
Latest Information Update: 16 Jul 2024
At a glance
- Drugs Regorafenib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Adverse reactions; Registrational
- Sponsors Bayer
- 18 Feb 2022 Status changed from active, no longer recruiting to completed.
- 25 Oct 2021 Planned End Date changed from 30 Sep 2021 to 31 Jan 2022.
- 17 Jan 2021 Planned End Date changed from 30 Jun 2021 to 30 Sep 2021.